FY2024 EPS Estimates for TG Therapeutics Raised by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2024 earnings estimates for TG Therapeutics in a research note issued on Tuesday, November 5th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the biopharmaceutical company will earn $0.10 per share for the year, up from their previous forecast of ($0.03). The consensus estimate for TG Therapeutics' current full-year earnings is $0.13 per share.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.65%. The company had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. During the same period in the prior year, the company earned $0.73 earnings per share. The firm's revenue was down 49.4% compared to the same quarter last year.

A number of other equities research analysts also recently weighed in on the company. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price for the company. B. Riley lifted their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research note on Wednesday, August 7th. The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday. Finally, HC Wainwright raised their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.67.

TG Therapeutics Stock Performance

NASDAQ:TGTX traded up $0.91 during mid-day trading on Friday, hitting $28.81. 2,794,793 shares of the stock were exchanged, compared to its average volume of 3,643,291. The firm's 50-day simple moving average is $23.73 and its 200 day simple moving average is $20.36. The stock has a market capitalization of $4.46 billion, a price-to-earnings ratio of -278.97 and a beta of 2.19. TG Therapeutics has a fifty-two week low of $9.81 and a fifty-two week high of $28.92. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TGTX. NBC Securities Inc. raised its position in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics during the 2nd quarter worth approximately $35,000. Blue Trust Inc. boosted its position in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in shares of TG Therapeutics during the third quarter worth $53,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of TG Therapeutics during the 1st quarter valued at $58,000. Institutional investors own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.